NeoGenomics, Inc. (NEO) 10-Year Financial Performance & Capital Metrics

NEO • • Industrial / General

HealthcareDiagnostics & ResearchClinical Laboratory ServicesSpecialized Testing Laboratories

AboutNeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.Show more

Revenue $661M +11.6%
EBITDA -$20M +44.4%
Net Income -$79M +10.5%
EPS (Diluted) -3.10 +11.4%
Gross Margin 43.92% +6.2%
EBITDA Margin -2.96% +50.2%
Operating Margin -13.94% +23.4%
Net Margin -11.92% +19.8%
ROE -8.54% +5.9%
ROIC -5.88% +7.1%
Debt/Equity 0.67 +3.3%
Interest Coverage -13.92 +10.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 87 (top 13%)
✓Strong 5Y sales CAGR of 10.1%
✓Trading at only 0.4x book value

✗Weaknesses

✗Negative free cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y22.46%

5Y10.07%

3Y10.9%

TTM10.1%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-45.98%

EPS CAGR

10Y-

5Y-

3Y-

TTM-44.26%

ROCE

10Y Avg-2.87%

5Y Avg-6.55%

3Y Avg-7.38%

Latest-6.3%

Peer Comparison

Specialized Testing Laboratories

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RDNTRadNet, Inc.	5.64B	72.99	1951.60	13.18%	-0.65%	-0.97%	0.8%	1.53
IDXXIDEXX Laboratories, Inc.	56.86B	712.12	66.74	6.46%	24.65%	65.81%	1.4%	0.62
CDNACareDx, Inc	1.06B	20.57	22.12	19.07%	16.97%	19.53%	2.98%	0.07
TRIBTrinity Biotech plc	13.23M	0.71	-0.40	8.31%	-73.78%
NEOGNeogen Corporation	2.06B	9.46	-1.88	-3.2%	-68.47%	-28.64%		0.44
STRRStar Equity Holdings, Inc.	38.07M	10.96	-2.76	-66.93%	-5.36%	-8.98%		0.03
BGLCBioNexus Gene Lab Corp.	8.72M	3.69	-4.10	-2.66%	-24.27%	-33.7%		0.03
NEONeoGenomics, Inc.	1.66B	12.83	-4.14	11.65%	-16%	-13.54%		0.67

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	99.8M	244.08M	240.25M	276.74M	408.83M	444.45M	484.33M	509.73M	591.64M	660.57M
Revenue Growth %	0.15%	1.45%	-0.02%	0.15%	0.48%	0.09%	0.09%	0.05%	0.16%	0.12%
Cost of Goods Sold+	56.05M	133.7M	138.29M	149.48M	211.99M	258.56M	297.27M	321.83M	347.04M	370.47M
COGS % of Revenue	0.56%	0.55%	0.58%	0.54%	0.52%	0.58%	0.61%	0.63%	0.59%	0.56%
Gross Profit+	43.76M	110.38M	101.96M	127.27M	196.84M	185.89M	187.06M	187.9M	244.6M	290.1M
Gross Margin %	0.44%	0.45%	0.42%	0.46%	0.48%	0.42%	0.39%	0.37%	0.41%	0.44%
Gross Profit Growth %	0.07%	1.52%	-0.08%	0.25%	0.55%	-0.06%	0.01%	0%	0.3%	0.19%
Operating Expenses+	49.39M	95.95M	99.05M	117.22M	183.83M	199.88M	305.81M	345.52M	352.34M	382.21M
OpEx % of Revenue	0.49%	0.39%	0.41%	0.42%	0.45%	0.45%	0.63%	0.68%	0.6%	0.58%
Selling, General & Admin	45.19M	87.84M	113.3M	114.22M	175.34M	191.66M	283.94M	277.91M	279.96M	310.49M
SG&A % of Revenue	0.45%	0.36%	0.47%	0.41%	0.43%	0.43%	0.59%	0.55%	0.47%	0.47%
Research & Development	4.2M	4.65M	3.64M	3M	8.49M	8.23M	21.87M	30.33M	27.31M	31.16M
R&D % of Revenue	0.04%	0.02%	0.02%	0.01%	0.02%	0.02%	0.05%	0.06%	0.05%	0.05%
Other Operating Expenses	0	3.46M	1.06M	14K	0	0	0	37.29M	45.07M	40.55M
Operating Income+	-5.63M	2.57M	2.9M	10.04M	13.01M	-13.99M	-118.75M	-157.62M	-107.74M	-92.11M
Operating Margin %	-0.06%	0.01%	0.01%	0.04%	0.03%	-0.03%	-0.25%	-0.31%	-0.18%	-0.14%
Operating Income Growth %	-3.54%	1.46%	0.13%	2.46%	0.3%	-2.08%	-7.49%	-0.33%	0.32%	0.15%
EBITDA+	1.51M	25.78M	25.49M	31.77M	43.28M	27.9M	-65.4M	-88.19M	-35.15M	-19.56M
EBITDA Margin %	0.02%	0.11%	0.11%	0.11%	0.11%	0.06%	-0.14%	-0.17%	-0.06%	-0.03%
EBITDA Growth %	-0.81%	16.11%	-0.01%	0.25%	0.36%	-0.36%	-3.34%	-0.35%	0.6%	0.44%
D&A (Non-Cash Add-back)	7.14M	23.21M	22.59M	21.73M	30.27M	41.89M	53.35M	69.43M	72.58M	72.55M
EBIT	-3.63M	2.15M	3.96M	10.04M	7.36M	-7.04M	-118.75M	-151.76M	-90.19M	-74.06M
Net Interest Income+	-854K	-10M	-5.54M	-6.23M	-3.71M	-7.02M	-5.08M	-1.51M	9.99M	11.81M
Interest Income	0	0	0	0	0	0	3.14M	6.08M	16.9M	18.43M
Interest Expense	854K	10M	5.54M	6.23M	3.71M	7.02M	8.22M	7.58M	6.91M	6.62M
Other Income/Expense	1.15M	-10M	-5.55M	-6.22M	-9.36M	-64K	103.68M	-1.72M	10.64M	11.43M
Pretax Income+	-4.49M	-7.42M	-2.65M	3.82M	3.65M	-14.06M	-15.07M	-159.34M	-97.1M	-80.67M
Pretax Margin %	-0.04%	-0.03%	-0.01%	0.01%	0.01%	-0.03%	-0.03%	-0.31%	-0.16%	-0.12%
Income Tax+	-1.95M	-1.7M	-2.25M	1.18M	-4.36M	-18.23M	-6.73M	-15.09M	-9.13M	-1.95M
Effective Tax Rate %	0.56%	0.83%	0.15%	0.69%	2.2%	-0.3%	0.55%	0.91%	0.91%	0.98%
Net Income+	-2.54M	-6.14M	-396K	2.64M	8.01M	4.17M	-8.35M	-144.25M	-87.97M	-78.73M
Net Margin %	-0.03%	-0.03%	-0%	0.01%	0.02%	0.01%	-0.02%	-0.28%	-0.15%	-0.12%
Net Income Growth %	-3.24%	-1.42%	0.94%	7.67%	2.03%	-0.48%	-3%	-16.28%	0.39%	0.11%
Net Income (Continuing)	-2.54M	-5.72M	-396K	2.64M	8.01M	4.17M	-8.35M	-144.25M	-87.97M	-78.73M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.21	-0.40	-0.03	0.14	0.39	0.19	-0.35	-5.80	-3.50	-3.10
EPS Growth %	-3.1%	-0.9%	0.94%	6.6%	1.79%	-0.51%	-2.84%	-15.57%	0.4%	0.11%
EPS (Basic)	-0.21	-0.39	-0.03	0.14	0.40	0.19	-0.35	-5.80	-3.50	-3.10
Diluted Shares Outstanding	12.11M	15.51M	15.89M	18.31M	20.72M	22.36M	23.99M	24.84M	25.1M	25.33M
Basic Shares Outstanding	12.11M	15.71M	15.89M	18.31M	20.09M	21.72M	23.99M	24.84M	25.1M	25.33M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	99.03M	78.83M	84.96M	103.67M	290.74M	448.73M	681.51M	605.29M	596.81M	596.02M
Cash & Short-Term Investments	23.42M	12.53M	12.82M	9.81M	173.02M	296.26M	515.39M	437.99M	415.2M	386.84M
Cash Only	23.42M	12.53M	12.82M	9.81M	173.02M	228.71M	316.83M	263.18M	342.49M	367.01M
Short-Term Investments	0	0	0	0	0	67.55M	198.56M	174.81M	72.72M	19.83M
Accounts Receivable	48.94M	55.51M	60.43M	76.92M	95.24M	106.84M	112.13M	119.71M	131.26M	150.54M
Days Sales Outstanding	179	83.01	91.8	101.45	85.03	87.74	84.5	85.72	80.98	83.18
Inventory	5.11M	6.25M	7.47M	8.65M	14.4M	29.53M	23.39M	24.28M	24.16M	26.75M
Days Inventory Outstanding	33.27	17.07	19.73	21.12	24.8	41.68	28.73	27.53	25.41	26.35
Other Current Assets	4.89M	4.54M	1M	561K	1.75M	4.55M	18.24M	8.08M	8.2M	11.72M
Total Non-Current Assets+	268.93M	258.29M	258.38M	401.35M	418.77M	539.6M	1.19B	1.13B	1.08B	1.04B
Property, Plant & Equipment	34.58M	34.04M	36.5M	60.89M	90.68M	151.89M	211.66M	198.61M	183.78M	173.69M
Fixed Asset Turnover	2.89x	7.17x	6.58x	4.55x	4.51x	2.93x	2.29x	2.57x	3.22x	3.80x
Goodwill	146.42M	147.02M	147.02M	197.89M	198.6M	211.08M	527.12M	522.77M	522.77M	522.77M
Intangible Assets	87.8M	77.06M	74.17M	140.03M	126.64M	120.65M	442.32M	408.26M	373.13M	339.68M
Long-Term Investments	-16.67M	-14.97M	-6.31M	-22.46M	153K	29.55M	236K	31K	0	0
Other Non-Current Assets	129K	174K	689K	2.54M	2.69M	21.01M	-48.54M	-29.67M	4.74M	5.89M
Total Assets+	367.95M	337.12M	343.34M	505.01M	709.51M	988.33M	1.87B	1.74B	1.68B	1.64B
Asset Turnover	0.27x	0.72x	0.70x	0.55x	0.58x	0.45x	0.26x	0.29x	0.35x	0.40x
Asset Growth %	3.54%	-0.08%	0.02%	0.47%	0.4%	0.39%	0.89%	-0.07%	-0.03%	-0.03%
Total Current Liabilities+	40.06M	59.91M	35.06M	60.92M	63.9M	73.18M	87.23M	89.93M	96.3M	301.24M
Accounts Payable	12.46M	16.78M	10.45M	17.78M	19.57M	24.96M	17.92M	20.51M	20.33M	21.61M
Days Payables Outstanding	81.17	45.81	27.58	43.41	33.69	35.24	22	23.26	21.39	21.29
Short-Term Debt	9.47M	3.84M	3.8M	14.17M	13.81M	2.84M	1.14M	0	0	200.78M
Deferred Revenue (Current)	-1000K	-1000K	-1000K	927K	1000K	1000K	1000K	1000K	1000K	409K
Other Current Liabilities	0	0	1.41M	2.69M	7.55M	0	16.66M	15.07M	53.16M	75.07M
Current Ratio	2.47x	1.32x	2.42x	1.70x	4.55x	6.13x	7.81x	6.73x	6.20x	1.98x
Quick Ratio	2.34x	1.21x	2.21x	1.56x	4.32x	5.73x	7.54x	6.46x	5.95x	1.89x
Cash Conversion Cycle	131.09	54.27	83.95	79.16	76.14	94.18	91.22	89.99	85	88.25
Total Non-Current Liabilities+	89.78M	90.61M	102.74M	123.65M	138.19M	220.85M	674.27M	652.08M	643.39M	434.46M
Long-Term Debt	52.34M	92.06M	91.15M	98.13M	91.83M	168.12M	532.48M	535.32M	538.2M	340.33M
Capital Lease Obligations	5.04M	5.38M	5.28M	0	27.23M	43.26M	72.29M	68.95M	67.87M	60.84M
Deferred Tax Liabilities	32.41M	14.97M	6.31M	22.46M	15.57M	5.42M	55.48M	34.75M	24.29M	21.51M
Other Non-Current Liabilities	0	0	6.97M	3.06M	2.4M	3.34M	13.03M	13.05M	13.03M	11.77M
Total Liabilities	129.84M	150.52M	137.81M	184.57M	202.1M	294.04M	761.5M	742.01M	739.69M	735.7M
Total Debt+	71.38M	106.17M	105.42M	112.3M	132.88M	218.22M	612.79M	610.93M	611.68M	605.33M
Net Debt	47.96M	93.64M	92.6M	102.49M	-40.14M	-10.49M	295.96M	347.75M	269.19M	238.32M
Debt / Equity	0.30x	0.57x	0.51x	0.35x	0.26x	0.31x	0.55x	0.61x	0.65x	0.67x
Debt / EBITDA	47.36x	4.12x	4.14x	3.53x	3.07x	7.82x	-	-	-	-
Net Debt / EBITDA	31.82x	3.63x	3.63x	3.23x	-0.93x	-0.38x	-	-	-	-
Interest Coverage	-6.60x	0.26x	0.52x	1.61x	3.50x	-1.99x	-14.45x	-20.79x	-15.60x	-13.92x
Total Equity+	238.11M	186.6M	205.53M	320.44M	507.41M	694.29M	1.11B	998.02M	941.54M	902.34M
Equity Growth %	2.94%	-0.22%	0.1%	0.56%	0.58%	0.37%	0.6%	-0.1%	-0.06%	-0.04%
Book Value per Share	19.67	12.03	12.94	17.50	24.49	31.05	46.19	40.17	37.51	35.62
Total Shareholders' Equity	238.11M	186.6M	205.53M	320.44M	507.41M	694.29M	1.11B	998.02M	941.54M	902.34M
Common Stock	76K	79K	80K	94K	105K	112K	124K	127K	127K	128K
Retained Earnings	-21.94M	-52.46M	-57.47M	-51.26M	-11.36M	-7.18M	-14.84M	-159.09M	-247.06M	-325.78M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-26.53M	-27.1M	274K	-579K	-1.62M	10K	-638K	-3.9M	-1.67M	-206K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	6.39M	21.48M	18.04M	44.79M	23.37M	1.46M	-26.72M	-65.99M	-1.95M	7.02M
Operating CF Margin %	0.06%	0.09%	0.08%	0.16%	0.06%	0%	-0.06%	-0.13%	-0%	0.01%
Operating CF Growth %	-0.32%	2.36%	-0.16%	1.48%	-0.48%	-0.94%	-19.3%	-1.47%	0.97%	4.6%
Net Income	-2.54M	-5.72M	-846K	2.64M	8.01M	4.17M	-8.35M	-144.25M	-87.97M	-78.73M
Depreciation & Amortization	7.14M	23.21M	22.59M	21.73M	30.27M	35.72M	53.35M	69.43M	72.58M	72.55M
Stock-Based Compensation	3.48M	5.44M	6.44M	6.96M	10M	10.21M	22.46M	24.67M	24.63M	33.41M
Deferred Taxes	-2.07M	15.32M	19.96M	404K	1.49M	951K	0	-16.1M	0	0
Other Non-Cash Items	2.32M	4.6M	440K	542K	6.03M	12.15M	-89.59M	31.95M	14.29M	12.42M
Working Capital Changes	-1.95M	-21.36M	-30.55M	12.51M	-32.42M	-61.75M	-4.6M	-31.7M	-25.49M	-32.63M
Change in Receivables	-3.21M	-18.43M	-24.24M	209K	-17.3M	-12.6M	-4.69M	-7.58M	-11.52M	-19.31M
Change in Inventory	-896K	-1.15M	-1.42M	734K	-5.75M	-15.2M	1.63M	-1.1M	-454K	-2.7M
Change in Payables	5.9M	-2.1M	-4.54M	12.92M	-9M	-3.97M	19.32M	2.79M	-4.55M	-4M
Cash from Investing+	-75.16M	-6.5M	-13.69M	-139.69M	-19.63M	-159.44M	-632.37M	517K	76.71M	12.86M
Capital Expenditures	-2.21M	-7.54M	-13.69M	-14.31M	-20.03M	-29.1M	-64.14M	-30.89M	-28.75M	-41.06M
CapEx % of Revenue	0.02%	0.03%	0.06%	0.05%	0.05%	0.07%	0.13%	0.06%	0.05%	0.06%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-72.94M	1.03M	0	0	0	0	-15M	12.1M	0	0
Cash from Financing+	58.49M	-25.87M	-4.09M	91.96M	159.47M	235.6M	725.28M	11.83M	4.55M	4.65M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-2.42M	-2.2M	0	-7.14M	0	-3.32M	-32.34M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	4.18M	13.94M	4.35M	30.48M	3.34M	-27.64M	-90.86M	-96.88M	-30.7M	-34.04M
FCF Margin %	0.04%	0.06%	0.02%	0.11%	0.01%	-0.06%	-0.19%	-0.19%	-0.05%	-0.05%
FCF Growth %	-0.26%	2.34%	-0.69%	6.01%	-0.89%	-9.27%	-2.29%	-0.07%	0.68%	-0.11%
FCF per Share	0.35	0.90	0.27	1.66	0.16	-1.24	-3.79	-3.90	-1.22	-1.34
FCF Conversion (FCF/Net Income)	-2.52x	-3.50x	-45.55x	16.96x	2.92x	0.35x	3.20x	0.46x	0.02x	-0.09x
Interest Paid	911K	5.42M	5.16M	0	4.78M	2.93M	3.06M	3.4M	3.38M	3.83M
Taxes Paid	25K	290K	284K	0	319K	246K	148K	180K	175K	207K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-1.7%	-2.89%	-0.2%	1%	1.93%	0.69%	-0.93%	-13.7%	-9.07%	-8.54%
Return on Invested Capital (ROIC)	-2.63%	0.68%	0.75%	2.09%	2.19%	-1.82%	-8.53%	-8.6%	-6.32%	-5.88%
Gross Margin	43.84%	45.22%	42.44%	45.99%	48.15%	41.83%	38.62%	36.86%	41.34%	43.92%
Net Margin	-2.54%	-2.52%	-0.16%	0.95%	1.96%	0.94%	-1.72%	-28.3%	-14.87%	-11.92%
Debt / Equity	0.30x	0.57x	0.51x	0.35x	0.26x	0.31x	0.55x	0.61x	0.65x	0.67x
Interest Coverage	-6.60x	0.26x	0.52x	1.61x	3.50x	-1.99x	-14.45x	-20.79x	-15.60x	-13.92x
FCF Conversion	-2.52x	-3.50x	-45.55x	16.96x	2.92x	0.35x	3.20x	0.46x	0.02x	-0.09x
Revenue Growth	14.62%	144.57%	-1.57%	15.19%	47.73%	8.71%	8.97%	5.24%	16.07%	11.65%

Revenue by Segment

	2017	2018	2019	2020	2021	2022	2023	2024
Commercial Insurance	-	-	-	-	-	-	-	99.84M
Commercial Insurance Growth	-	-	-	-	-	-	-	-
Clinical Services	-	241.87M	361.16M	382.34M	404.17M	418.75M	495.64M	-
Clinical Services Growth	-	-	49.32%	5.86%	5.71%	3.61%	18.36%	-
Pharma Services	-	34.87M	47.67M	62.11M	80.16M	90.97M	-	-
Pharma Services Growth	-	-	36.71%	30.30%	29.05%	13.49%	-	-
Clinical Services	231.75M	-	-	-	-	-	-	-
Clinical Services Growth	-	-	-	-	-	-	-	-
Pharma Services	26.86M	-	-	-	-	-	-	-
Pharma Services Growth	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

NeoGenomics, Inc. (NEO) reported $709.2M in revenue for fiscal year 2024. This represents a 1531% increase from $43.5M in 2011.

NeoGenomics, Inc. (NEO) grew revenue by 11.6% over the past year. This is steady growth.

NeoGenomics, Inc. (NEO) reported a net loss of $113.5M for fiscal year 2024.

Dividend & Returns

NeoGenomics, Inc. (NEO) has a return on equity (ROE) of -8.5%. Negative ROE indicates the company is unprofitable.

NeoGenomics, Inc. (NEO) had negative free cash flow of $17.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

NeoGenomics, Inc. (NEO) 10-Year Financial Performance & Capital Metrics

NEO • • Industrial / General

HealthcareDiagnostics & ResearchClinical Laboratory ServicesSpecialized Testing Laboratories

Revenue $661M +11.6%
EBITDA -$20M +44.4%
Net Income -$79M +10.5%
EPS (Diluted) -3.10 +11.4%
Gross Margin 43.92% +6.2%
EBITDA Margin -2.96% +50.2%
Operating Margin -13.94% +23.4%
Net Margin -11.92% +19.8%
ROE -8.54% +5.9%
ROIC -5.88% +7.1%
Debt/Equity 0.67 +3.3%
Interest Coverage -13.92 +10.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 87 (top 13%)
✓Strong 5Y sales CAGR of 10.1%
✓Trading at only 0.4x book value

✗Weaknesses

✗Negative free cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y22.46%

5Y10.07%

3Y10.9%

TTM10.1%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-45.98%

EPS CAGR

10Y-

5Y-

3Y-

TTM-44.26%

ROCE

10Y Avg-2.87%

5Y Avg-6.55%

3Y Avg-7.38%

Latest-6.3%

Peer Comparison

Specialized Testing Laboratories

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RDNTRadNet, Inc.	5.64B	72.99	1951.60	13.18%	-0.65%	-0.97%	0.8%	1.53
IDXXIDEXX Laboratories, Inc.	56.86B	712.12	66.74	6.46%	24.65%	65.81%	1.4%	0.62
CDNACareDx, Inc	1.06B	20.57	22.12	19.07%	16.97%	19.53%	2.98%	0.07
TRIBTrinity Biotech plc	13.23M	0.71	-0.40	8.31%	-73.78%
NEOGNeogen Corporation	2.06B	9.46	-1.88	-3.2%	-68.47%	-28.64%		0.44
STRRStar Equity Holdings, Inc.	38.07M	10.96	-2.76	-66.93%	-5.36%	-8.98%		0.03
BGLCBioNexus Gene Lab Corp.	8.72M	3.69	-4.10	-2.66%	-24.27%	-33.7%		0.03
NEONeoGenomics, Inc.	1.66B	12.83	-4.14	11.65%	-16%	-13.54%		0.67

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	99.8M	244.08M	240.25M	276.74M	408.83M	444.45M	484.33M	509.73M	591.64M	660.57M
Revenue Growth %	0.15%	1.45%	-0.02%	0.15%	0.48%	0.09%	0.09%	0.05%	0.16%	0.12%
Cost of Goods Sold+	56.05M	133.7M	138.29M	149.48M	211.99M	258.56M	297.27M	321.83M	347.04M	370.47M
COGS % of Revenue	0.56%	0.55%	0.58%	0.54%	0.52%	0.58%	0.61%	0.63%	0.59%	0.56%
Gross Profit+	43.76M	110.38M	101.96M	127.27M	196.84M	185.89M	187.06M	187.9M	244.6M	290.1M
Gross Margin %	0.44%	0.45%	0.42%	0.46%	0.48%	0.42%	0.39%	0.37%	0.41%	0.44%
Gross Profit Growth %	0.07%	1.52%	-0.08%	0.25%	0.55%	-0.06%	0.01%	0%	0.3%	0.19%
Operating Expenses+	49.39M	95.95M	99.05M	117.22M	183.83M	199.88M	305.81M	345.52M	352.34M	382.21M
OpEx % of Revenue	0.49%	0.39%	0.41%	0.42%	0.45%	0.45%	0.63%	0.68%	0.6%	0.58%
Selling, General & Admin	45.19M	87.84M	113.3M	114.22M	175.34M	191.66M	283.94M	277.91M	279.96M	310.49M
SG&A % of Revenue	0.45%	0.36%	0.47%	0.41%	0.43%	0.43%	0.59%	0.55%	0.47%	0.47%
Research & Development	4.2M	4.65M	3.64M	3M	8.49M	8.23M	21.87M	30.33M	27.31M	31.16M
R&D % of Revenue	0.04%	0.02%	0.02%	0.01%	0.02%	0.02%	0.05%	0.06%	0.05%	0.05%
Other Operating Expenses	0	3.46M	1.06M	14K	0	0	0	37.29M	45.07M	40.55M
Operating Income+	-5.63M	2.57M	2.9M	10.04M	13.01M	-13.99M	-118.75M	-157.62M	-107.74M	-92.11M
Operating Margin %	-0.06%	0.01%	0.01%	0.04%	0.03%	-0.03%	-0.25%	-0.31%	-0.18%	-0.14%
Operating Income Growth %	-3.54%	1.46%	0.13%	2.46%	0.3%	-2.08%	-7.49%	-0.33%	0.32%	0.15%
EBITDA+	1.51M	25.78M	25.49M	31.77M	43.28M	27.9M	-65.4M	-88.19M	-35.15M	-19.56M
EBITDA Margin %	0.02%	0.11%	0.11%	0.11%	0.11%	0.06%	-0.14%	-0.17%	-0.06%	-0.03%
EBITDA Growth %	-0.81%	16.11%	-0.01%	0.25%	0.36%	-0.36%	-3.34%	-0.35%	0.6%	0.44%
D&A (Non-Cash Add-back)	7.14M	23.21M	22.59M	21.73M	30.27M	41.89M	53.35M	69.43M	72.58M	72.55M
EBIT	-3.63M	2.15M	3.96M	10.04M	7.36M	-7.04M	-118.75M	-151.76M	-90.19M	-74.06M
Net Interest Income+	-854K	-10M	-5.54M	-6.23M	-3.71M	-7.02M	-5.08M	-1.51M	9.99M	11.81M
Interest Income	0	0	0	0	0	0	3.14M	6.08M	16.9M	18.43M
Interest Expense	854K	10M	5.54M	6.23M	3.71M	7.02M	8.22M	7.58M	6.91M	6.62M
Other Income/Expense	1.15M	-10M	-5.55M	-6.22M	-9.36M	-64K	103.68M	-1.72M	10.64M	11.43M
Pretax Income+	-4.49M	-7.42M	-2.65M	3.82M	3.65M	-14.06M	-15.07M	-159.34M	-97.1M	-80.67M
Pretax Margin %	-0.04%	-0.03%	-0.01%	0.01%	0.01%	-0.03%	-0.03%	-0.31%	-0.16%	-0.12%
Income Tax+	-1.95M	-1.7M	-2.25M	1.18M	-4.36M	-18.23M	-6.73M	-15.09M	-9.13M	-1.95M
Effective Tax Rate %	0.56%	0.83%	0.15%	0.69%	2.2%	-0.3%	0.55%	0.91%	0.91%	0.98%
Net Income+	-2.54M	-6.14M	-396K	2.64M	8.01M	4.17M	-8.35M	-144.25M	-87.97M	-78.73M
Net Margin %	-0.03%	-0.03%	-0%	0.01%	0.02%	0.01%	-0.02%	-0.28%	-0.15%	-0.12%
Net Income Growth %	-3.24%	-1.42%	0.94%	7.67%	2.03%	-0.48%	-3%	-16.28%	0.39%	0.11%
Net Income (Continuing)	-2.54M	-5.72M	-396K	2.64M	8.01M	4.17M	-8.35M	-144.25M	-87.97M	-78.73M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.21	-0.40	-0.03	0.14	0.39	0.19	-0.35	-5.80	-3.50	-3.10
EPS Growth %	-3.1%	-0.9%	0.94%	6.6%	1.79%	-0.51%	-2.84%	-15.57%	0.4%	0.11%
EPS (Basic)	-0.21	-0.39	-0.03	0.14	0.40	0.19	-0.35	-5.80	-3.50	-3.10
Diluted Shares Outstanding	12.11M	15.51M	15.89M	18.31M	20.72M	22.36M	23.99M	24.84M	25.1M	25.33M
Basic Shares Outstanding	12.11M	15.71M	15.89M	18.31M	20.09M	21.72M	23.99M	24.84M	25.1M	25.33M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	99.03M	78.83M	84.96M	103.67M	290.74M	448.73M	681.51M	605.29M	596.81M	596.02M
Cash & Short-Term Investments	23.42M	12.53M	12.82M	9.81M	173.02M	296.26M	515.39M	437.99M	415.2M	386.84M
Cash Only	23.42M	12.53M	12.82M	9.81M	173.02M	228.71M	316.83M	263.18M	342.49M	367.01M
Short-Term Investments	0	0	0	0	0	67.55M	198.56M	174.81M	72.72M	19.83M
Accounts Receivable	48.94M	55.51M	60.43M	76.92M	95.24M	106.84M	112.13M	119.71M	131.26M	150.54M
Days Sales Outstanding	179	83.01	91.8	101.45	85.03	87.74	84.5	85.72	80.98	83.18
Inventory	5.11M	6.25M	7.47M	8.65M	14.4M	29.53M	23.39M	24.28M	24.16M	26.75M
Days Inventory Outstanding	33.27	17.07	19.73	21.12	24.8	41.68	28.73	27.53	25.41	26.35
Other Current Assets	4.89M	4.54M	1M	561K	1.75M	4.55M	18.24M	8.08M	8.2M	11.72M
Total Non-Current Assets+	268.93M	258.29M	258.38M	401.35M	418.77M	539.6M	1.19B	1.13B	1.08B	1.04B
Property, Plant & Equipment	34.58M	34.04M	36.5M	60.89M	90.68M	151.89M	211.66M	198.61M	183.78M	173.69M
Fixed Asset Turnover	2.89x	7.17x	6.58x	4.55x	4.51x	2.93x	2.29x	2.57x	3.22x	3.80x
Goodwill	146.42M	147.02M	147.02M	197.89M	198.6M	211.08M	527.12M	522.77M	522.77M	522.77M
Intangible Assets	87.8M	77.06M	74.17M	140.03M	126.64M	120.65M	442.32M	408.26M	373.13M	339.68M
Long-Term Investments	-16.67M	-14.97M	-6.31M	-22.46M	153K	29.55M	236K	31K	0	0
Other Non-Current Assets	129K	174K	689K	2.54M	2.69M	21.01M	-48.54M	-29.67M	4.74M	5.89M
Total Assets+	367.95M	337.12M	343.34M	505.01M	709.51M	988.33M	1.87B	1.74B	1.68B	1.64B
Asset Turnover	0.27x	0.72x	0.70x	0.55x	0.58x	0.45x	0.26x	0.29x	0.35x	0.40x
Asset Growth %	3.54%	-0.08%	0.02%	0.47%	0.4%	0.39%	0.89%	-0.07%	-0.03%	-0.03%
Total Current Liabilities+	40.06M	59.91M	35.06M	60.92M	63.9M	73.18M	87.23M	89.93M	96.3M	301.24M
Accounts Payable	12.46M	16.78M	10.45M	17.78M	19.57M	24.96M	17.92M	20.51M	20.33M	21.61M
Days Payables Outstanding	81.17	45.81	27.58	43.41	33.69	35.24	22	23.26	21.39	21.29
Short-Term Debt	9.47M	3.84M	3.8M	14.17M	13.81M	2.84M	1.14M	0	0	200.78M
Deferred Revenue (Current)	-1000K	-1000K	-1000K	927K	1000K	1000K	1000K	1000K	1000K	409K
Other Current Liabilities	0	0	1.41M	2.69M	7.55M	0	16.66M	15.07M	53.16M	75.07M
Current Ratio	2.47x	1.32x	2.42x	1.70x	4.55x	6.13x	7.81x	6.73x	6.20x	1.98x
Quick Ratio	2.34x	1.21x	2.21x	1.56x	4.32x	5.73x	7.54x	6.46x	5.95x	1.89x
Cash Conversion Cycle	131.09	54.27	83.95	79.16	76.14	94.18	91.22	89.99	85	88.25
Total Non-Current Liabilities+	89.78M	90.61M	102.74M	123.65M	138.19M	220.85M	674.27M	652.08M	643.39M	434.46M
Long-Term Debt	52.34M	92.06M	91.15M	98.13M	91.83M	168.12M	532.48M	535.32M	538.2M	340.33M
Capital Lease Obligations	5.04M	5.38M	5.28M	0	27.23M	43.26M	72.29M	68.95M	67.87M	60.84M
Deferred Tax Liabilities	32.41M	14.97M	6.31M	22.46M	15.57M	5.42M	55.48M	34.75M	24.29M	21.51M
Other Non-Current Liabilities	0	0	6.97M	3.06M	2.4M	3.34M	13.03M	13.05M	13.03M	11.77M
Total Liabilities	129.84M	150.52M	137.81M	184.57M	202.1M	294.04M	761.5M	742.01M	739.69M	735.7M
Total Debt+	71.38M	106.17M	105.42M	112.3M	132.88M	218.22M	612.79M	610.93M	611.68M	605.33M
Net Debt	47.96M	93.64M	92.6M	102.49M	-40.14M	-10.49M	295.96M	347.75M	269.19M	238.32M
Debt / Equity	0.30x	0.57x	0.51x	0.35x	0.26x	0.31x	0.55x	0.61x	0.65x	0.67x
Debt / EBITDA	47.36x	4.12x	4.14x	3.53x	3.07x	7.82x	-	-	-	-
Net Debt / EBITDA	31.82x	3.63x	3.63x	3.23x	-0.93x	-0.38x	-	-	-	-
Interest Coverage	-6.60x	0.26x	0.52x	1.61x	3.50x	-1.99x	-14.45x	-20.79x	-15.60x	-13.92x
Total Equity+	238.11M	186.6M	205.53M	320.44M	507.41M	694.29M	1.11B	998.02M	941.54M	902.34M
Equity Growth %	2.94%	-0.22%	0.1%	0.56%	0.58%	0.37%	0.6%	-0.1%	-0.06%	-0.04%
Book Value per Share	19.67	12.03	12.94	17.50	24.49	31.05	46.19	40.17	37.51	35.62
Total Shareholders' Equity	238.11M	186.6M	205.53M	320.44M	507.41M	694.29M	1.11B	998.02M	941.54M	902.34M
Common Stock	76K	79K	80K	94K	105K	112K	124K	127K	127K	128K
Retained Earnings	-21.94M	-52.46M	-57.47M	-51.26M	-11.36M	-7.18M	-14.84M	-159.09M	-247.06M	-325.78M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-26.53M	-27.1M	274K	-579K	-1.62M	10K	-638K	-3.9M	-1.67M	-206K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	6.39M	21.48M	18.04M	44.79M	23.37M	1.46M	-26.72M	-65.99M	-1.95M	7.02M
Operating CF Margin %	0.06%	0.09%	0.08%	0.16%	0.06%	0%	-0.06%	-0.13%	-0%	0.01%
Operating CF Growth %	-0.32%	2.36%	-0.16%	1.48%	-0.48%	-0.94%	-19.3%	-1.47%	0.97%	4.6%
Net Income	-2.54M	-5.72M	-846K	2.64M	8.01M	4.17M	-8.35M	-144.25M	-87.97M	-78.73M
Depreciation & Amortization	7.14M	23.21M	22.59M	21.73M	30.27M	35.72M	53.35M	69.43M	72.58M	72.55M
Stock-Based Compensation	3.48M	5.44M	6.44M	6.96M	10M	10.21M	22.46M	24.67M	24.63M	33.41M
Deferred Taxes	-2.07M	15.32M	19.96M	404K	1.49M	951K	0	-16.1M	0	0
Other Non-Cash Items	2.32M	4.6M	440K	542K	6.03M	12.15M	-89.59M	31.95M	14.29M	12.42M
Working Capital Changes	-1.95M	-21.36M	-30.55M	12.51M	-32.42M	-61.75M	-4.6M	-31.7M	-25.49M	-32.63M
Change in Receivables	-3.21M	-18.43M	-24.24M	209K	-17.3M	-12.6M	-4.69M	-7.58M	-11.52M	-19.31M
Change in Inventory	-896K	-1.15M	-1.42M	734K	-5.75M	-15.2M	1.63M	-1.1M	-454K	-2.7M
Change in Payables	5.9M	-2.1M	-4.54M	12.92M	-9M	-3.97M	19.32M	2.79M	-4.55M	-4M
Cash from Investing+	-75.16M	-6.5M	-13.69M	-139.69M	-19.63M	-159.44M	-632.37M	517K	76.71M	12.86M
Capital Expenditures	-2.21M	-7.54M	-13.69M	-14.31M	-20.03M	-29.1M	-64.14M	-30.89M	-28.75M	-41.06M
CapEx % of Revenue	0.02%	0.03%	0.06%	0.05%	0.05%	0.07%	0.13%	0.06%	0.05%	0.06%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-72.94M	1.03M	0	0	0	0	-15M	12.1M	0	0
Cash from Financing+	58.49M	-25.87M	-4.09M	91.96M	159.47M	235.6M	725.28M	11.83M	4.55M	4.65M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-2.42M	-2.2M	0	-7.14M	0	-3.32M	-32.34M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	4.18M	13.94M	4.35M	30.48M	3.34M	-27.64M	-90.86M	-96.88M	-30.7M	-34.04M
FCF Margin %	0.04%	0.06%	0.02%	0.11%	0.01%	-0.06%	-0.19%	-0.19%	-0.05%	-0.05%
FCF Growth %	-0.26%	2.34%	-0.69%	6.01%	-0.89%	-9.27%	-2.29%	-0.07%	0.68%	-0.11%
FCF per Share	0.35	0.90	0.27	1.66	0.16	-1.24	-3.79	-3.90	-1.22	-1.34
FCF Conversion (FCF/Net Income)	-2.52x	-3.50x	-45.55x	16.96x	2.92x	0.35x	3.20x	0.46x	0.02x	-0.09x
Interest Paid	911K	5.42M	5.16M	0	4.78M	2.93M	3.06M	3.4M	3.38M	3.83M
Taxes Paid	25K	290K	284K	0	319K	246K	148K	180K	175K	207K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-1.7%	-2.89%	-0.2%	1%	1.93%	0.69%	-0.93%	-13.7%	-9.07%	-8.54%
Return on Invested Capital (ROIC)	-2.63%	0.68%	0.75%	2.09%	2.19%	-1.82%	-8.53%	-8.6%	-6.32%	-5.88%
Gross Margin	43.84%	45.22%	42.44%	45.99%	48.15%	41.83%	38.62%	36.86%	41.34%	43.92%
Net Margin	-2.54%	-2.52%	-0.16%	0.95%	1.96%	0.94%	-1.72%	-28.3%	-14.87%	-11.92%
Debt / Equity	0.30x	0.57x	0.51x	0.35x	0.26x	0.31x	0.55x	0.61x	0.65x	0.67x
Interest Coverage	-6.60x	0.26x	0.52x	1.61x	3.50x	-1.99x	-14.45x	-20.79x	-15.60x	-13.92x
FCF Conversion	-2.52x	-3.50x	-45.55x	16.96x	2.92x	0.35x	3.20x	0.46x	0.02x	-0.09x
Revenue Growth	14.62%	144.57%	-1.57%	15.19%	47.73%	8.71%	8.97%	5.24%	16.07%	11.65%

Revenue by Segment

	2017	2018	2019	2020	2021	2022	2023	2024
Commercial Insurance	-	-	-	-	-	-	-	99.84M
Commercial Insurance Growth	-	-	-	-	-	-	-	-
Clinical Services	-	241.87M	361.16M	382.34M	404.17M	418.75M	495.64M	-
Clinical Services Growth	-	-	49.32%	5.86%	5.71%	3.61%	18.36%	-
Pharma Services	-	34.87M	47.67M	62.11M	80.16M	90.97M	-	-
Pharma Services Growth	-	-	36.71%	30.30%	29.05%	13.49%	-	-
Clinical Services	231.75M	-	-	-	-	-	-	-
Clinical Services Growth	-	-	-	-	-	-	-	-
Pharma Services	26.86M	-	-	-	-	-	-	-
Pharma Services Growth	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

NeoGenomics, Inc. (NEO) reported $709.2M in revenue for fiscal year 2024. This represents a 1531% increase from $43.5M in 2011.

NeoGenomics, Inc. (NEO) grew revenue by 11.6% over the past year. This is steady growth.

NeoGenomics, Inc. (NEO) reported a net loss of $113.5M for fiscal year 2024.

Dividend & Returns

NeoGenomics, Inc. (NEO) has a return on equity (ROE) of -8.5%. Negative ROE indicates the company is unprofitable.

NeoGenomics, Inc. (NEO) had negative free cash flow of $17.0M in fiscal year 2024, likely due to heavy capital investments.